Literature DB >> 16904243

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

M Nistor1, M Don, M Parekh, F Sarsoza, M Goodus, G E Lopez, C Kawas, J Leverenz, E Doran, I T Lott, M Hill, E Head.   

Abstract

Aged individuals with Down syndrome (DS) develop Alzheimer's disease (AD) neuropathology by the age of 40 years. The purpose of the current study was to measure age-associated changes in APP processing in 36 individuals with DS (5 months-69 years) and in 26 controls (5 months-100 years). Alpha-secretase significantly decreased with age in DS, particularly in cases over the age of 40 years and was stable in controls. The levels of C-terminal fragments of APP reflecting alpha-secretase processing (CTF-alpha) decreased with age in both groups. In both groups, there was significant increase in beta-secretase activity with age. CTF-beta remained constant with age in controls suggesting compensatory increases in turnover/clearance mechanisms. In DS, young individuals had the lowest CTF-beta levels that may reflect rapid conversion of beta-amyloid (Abeta) to soluble pools or efficient CTF-beta clearance mechanisms. Treatments to slow or prevent AD in the general population targeting secretase activity may be more efficacious in adults with DS if combined with approaches that enhance Abeta degradation and clearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904243      PMCID: PMC3375834          DOI: 10.1016/j.neurobiolaging.2006.06.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  69 in total

1.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.

Authors:  Anne Rovelet-Lecrux; Didier Hannequin; Gregory Raux; Nathalie Le Meur; Annie Laquerrière; Anne Vital; Cécile Dumanchin; Sébastien Feuillette; Alexis Brice; Martine Vercelletto; Frédéric Dubas; Thierry Frebourg; Dominique Campion
Journal:  Nat Genet       Date:  2005-12-20       Impact factor: 38.330

2.  The synaptic Abeta hypothesis of Alzheimer disease.

Authors:  Rudolph E Tanzi
Journal:  Nat Neurosci       Date:  2005-08       Impact factor: 24.884

3.  Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

Authors:  Kavon Rezai-Zadeh; Doug Shytle; Nan Sun; Takashi Mori; Huayan Hou; Deborah Jeanniton; Jared Ehrhart; Kirk Townsend; Jin Zeng; David Morgan; John Hardy; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2005-09-21       Impact factor: 6.167

4.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.

Authors:  B Rumble; R Retallack; C Hilbich; G Simms; G Multhaup; R Martins; A Hockey; P Montgomery; K Beyreuther; C L Masters
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

5.  Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

Authors:  Fiona Pickford; Jungsu Kim; Eileen McGowan; Luisa Onstead; Jason Eriksen; Cindy Yu; Lisa Skipper; M Paul Murphy; Jenny Beard; Pritam Das; Karen Jansen; Michael DeLucia; Wen-Lang Lin; Georgia Dolios; Rong Wang; Christopher B Eckman; Dennis W Dickson; Mike Hutton; John Hardy; Todd Golde
Journal:  Neuron       Date:  2005-07-21       Impact factor: 17.173

6.  Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.

Authors:  Tara L Spires; Melanie Meyer-Luehmann; Edward A Stern; Pamela J McLean; Jesse Skoch; Paul T Nguyen; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

7.  Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment.

Authors:  C Nordstedt; S E Gandy; I Alafuzoff; G L Caporaso; K Iverfeldt; J A Grebb; B Winblad; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome.

Authors:  D M Mann; M M Esiri
Journal:  J Neurol Sci       Date:  1989-02       Impact factor: 3.181

9.  A prospective study of Alzheimer disease in Down syndrome.

Authors:  F Lai; R S Williams
Journal:  Arch Neurol       Date:  1989-08

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  50 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Drugs for Alzheimer's disease.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

3.  Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines.

Authors:  Viorela Pop; Elizabeth Head; Nicole C Berchtold; Charles G Glabe; Christa M Studzinski; Adam M Weidner; M Paul Murphy; Carl W Cotman
Journal:  Neurobiol Aging       Date:  2010-04-30       Impact factor: 4.673

4.  BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog.

Authors:  Margaret Fahnestock; Monica Marchese; Elizabeth Head; Viorela Pop; Bernadeta Michalski; William N Milgram; Carl W Cotman
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

Review 5.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

6.  Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Authors:  Giovanna Cenini; Amy L S Dowling; Tina L Beckett; Eugenio Barone; Cesare Mancuso; Michael Paul Murphy; Harry Levine; Ira T Lott; Frederick A Schmitt; D Allan Butterfield; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

7.  Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease.

Authors:  Emily R Rosario; Lilly Chang; Elizabeth H Head; Frank Z Stanczyk; Christian J Pike
Journal:  Neurobiol Aging       Date:  2009-05-09       Impact factor: 4.673

Review 8.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.

Authors:  Hans-Gert Bernstein; Rolf Stricker; Uwe Lendeckel; Iris Bertram; Henrik Dobrowolny; Johann Steiner; Bernhard Bogerts; Georg Reiser
Journal:  Age (Dordr)       Date:  2008-08-30

10.  Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis.

Authors:  Antoinette R Bailey; Brian N Giunta; Demian Obregon; William V Nikolic; Jun Tian; Cyndy D Sanberg; Danielle T Sutton; Jun Tan
Journal:  Int J Clin Exp Med       Date:  2008-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.